On the road to effectively treating cancer

Most diseases are complex, and cancer is no exception. The Biopharmaceutical company Symphogen is world leading in designing highly innovative and better treatments for cancer by using antibody mixtures. In collaboration with the NXUS project, key structural details of the antibodies in an oncology product have been investigated, using advanced solution based small-angle X-ray scattering (SAXS) at leading international synchrotrons.

The collaboration with the NXUS project revealed key structural similarities between the examined antibodies. However, subtle structural differences from the expected structure were visible from the data. These were quantified by advanced data modelling, providing Symphogen with specialized and specific knowledge that is not equally obtainable in other ways. This enables Symphogen to rationally design and optimize the next generation of cancer treatment drugs.

Contact: NXUS: Lise Arleth, arleth@nbi.ku.dk
Symphogen: Johan Lantto, jol@symphogen.com
www.NXUS.dk